SPIKIMM, a biotech company founded by Truffle Capital and Institut Pasteur, announce that SPK001, its monoclonal antibody has demonstrated a potent and broad neutralization activity across all SARS-COV-2 variants of concern, including Omicron (BA.1 AND BA.2)

The monoclonal antibody SPK001, SpikImm’s lead candidate originally developed in the Humoral Immunology lab headed by Dr Hugo Mouquet at the Institut Pasteur (joint research unit Inserm), has demonstrated a potent and broad neutralization activity in vitro against SARS-CoV-2 and all variants of concern (including Delta and Omicron), as well as in vivo prophylactic and therapeutic efficacies in mouse and hamster models. As most monoclonal antibodies commercially-available and in clinics partially or completely lost their effectiveness against omicron variants BA.1 and BA.2 (dominant worldwide since Dec 2021), SPK001 now appears as one of the most promising mAbs